drug
(ertugliflozin + metformin hydrochloride)
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Trials studying (ertugliflozin + metformin hydrochloride)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 13, 2030
~3.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030method-of-use (U-2214)US 94399024.2y
- Oct 21, 2030method-of-use (U-2214)US 94399024.2y
- Oct 21, 2030method-of-use (U-2214)US 94399024.2y
- Oct 21, 2030method-of-use (U-2214)US 94399024.2y
- Jul 13, 2030compositionUS 80805803.9y
- Jul 13, 2030compositionUS 80805803.9y
- Jul 13, 2030compositionUS 80805803.9y
- Jul 13, 2030compositionUS 80805803.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that